Les traitements antérieurs affectent-ils les risques ?
Oui, des traitements antérieurs peuvent influencer la réponse aux thérapies CRISPR.
Traitements antérieursRéponseProtéines CRISPR
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines associées aux CRISPR : Questions médicales les plus fréquentes",
"headline": "Protéines associées aux CRISPR : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines associées aux CRISPR : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-15",
"dateModified": "2025-02-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines associées aux CRISPR"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines",
"url": "https://questionsmedicales.fr/mesh/D011506",
"about": {
"@type": "MedicalCondition",
"name": "Protéines",
"code": {
"@type": "MedicalCode",
"code": "D011506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine-9 associée à CRISPR",
"alternateName": "CRISPR-Associated Protein 9",
"url": "https://questionsmedicales.fr/mesh/D000076987",
"about": {
"@type": "MedicalCondition",
"name": "Protéine-9 associée à CRISPR",
"code": {
"@type": "MedicalCode",
"code": "D000076987",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.212.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protéines associées aux CRISPR",
"alternateName": "CRISPR-Associated Proteins",
"code": {
"@type": "MedicalCode",
"code": "D064130",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yi Zhang",
"url": "https://questionsmedicales.fr/author/Yi%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China."
}
},
{
"@type": "Person",
"name": "Yue Feng",
"url": "https://questionsmedicales.fr/author/Yue%20Feng",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Electronic address: fengyue@mail.buct.edu.cn."
}
},
{
"@type": "Person",
"name": "Joseph Bondy-Denomy",
"url": "https://questionsmedicales.fr/author/Joseph%20Bondy-Denomy",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94143, USA."
}
},
{
"@type": "Person",
"name": "Alan R Davidson",
"url": "https://questionsmedicales.fr/author/Alan%20R%20Davidson",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: alan.davidson@utoronto.ca."
}
},
{
"@type": "Person",
"name": "Xu Peng",
"url": "https://questionsmedicales.fr/author/Xu%20Peng",
"affiliation": {
"@type": "Organization",
"name": "Department of Biology, University of Copenhagen, Copenhagen N, Denmark. Electronic address: peng@bio.ku.dk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Modern Innovations in Breast Surgery: Robotic Breast Surgery and Robotic Breast Reconstruction.",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36813413",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cps.2022.11.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Breast density analysis of digital breast tomosynthesis.",
"datePublished": "2023-10-31",
"url": "https://questionsmedicales.fr/article/37907569",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-45402-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Breast Density and Breast Cancer Screening with Digital Breast Tomosynthesis: A TOSYMA Trial Subanalysis.",
"datePublished": "2022-10-04",
"url": "https://questionsmedicales.fr/article/36194110",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1148/radiol.221006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial.",
"datePublished": "2022-08-05",
"url": "https://questionsmedicales.fr/article/35930754",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1200/JCO.22.00451"
}
},
{
"@type": "ScholarlyArticle",
"name": "Male breast cancer presenting in accessory axillary breast.",
"datePublished": "2022-06-15",
"url": "https://questionsmedicales.fr/article/35704511",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jcu.23250"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines associées aux CRISPR",
"item": "https://questionsmedicales.fr/mesh/D064130"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines associées aux CRISPR - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines associées aux CRISPR",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines associées aux CRISPR",
"description": "Comment identifier les protéines CRISPR dans un échantillon ?\nQuels tests sont utilisés pour détecter les protéines associées ?\nPeut-on détecter les protéines CRISPR par imagerie ?\nQuels marqueurs sont spécifiques aux protéines CRISPR ?\nComment évaluer l'activité des protéines CRISPR ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Breast#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines associées aux CRISPR",
"description": "Quels symptômes sont liés à des dysfonctionnements CRISPR ?\nLes protéines CRISPR causent-elles des effets secondaires ?\nComment les protéines CRISPR affectent-elles la santé ?\nY a-t-il des symptômes d'allergie aux protéines CRISPR ?\nLes protéines CRISPR peuvent-elles provoquer des cancers ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Breast#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines associées aux CRISPR",
"description": "Comment prévenir les maladies liées aux protéines CRISPR ?\nLes vaccins peuvent-ils intégrer CRISPR ?\nY a-t-il des mesures préventives pour les traitements CRISPR ?\nComment éduquer sur les risques des CRISPR ?\nLes tests génétiques peuvent-ils prévenir des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Breast#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines associées aux CRISPR",
"description": "Comment les protéines CRISPR sont-elles utilisées en thérapie ?\nQuels types de maladies peuvent être traités avec CRISPR ?\nY a-t-il des traitements en cours avec CRISPR ?\nQuels sont les défis des traitements CRISPR ?\nCRISPR peut-il être utilisé pour des maladies infectieuses ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Breast#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines associées aux CRISPR",
"description": "Quelles complications peuvent survenir avec CRISPR ?\nComment gérer les complications des traitements CRISPR ?\nLes complications sont-elles fréquentes avec CRISPR ?\nQuelles sont les conséquences des effets hors cible ?\nLes complications peuvent-elles être réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Breast#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines associées aux CRISPR",
"description": "Quels sont les facteurs de risque pour les traitements CRISPR ?\nLes mutations génétiques augmentent-elles les risques ?\nL'environnement influence-t-il les risques liés à CRISPR ?\nLes antécédents familiaux sont-ils un facteur de risque ?\nLes traitements antérieurs affectent-ils les risques ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Breast#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les protéines CRISPR dans un échantillon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques comme la PCR et le séquençage."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les protéines associées ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'immunobuvardage et de chromatographie peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les protéines CRISPR par imagerie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques comme la microscopie à fluorescence peuvent être utilisées."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont spécifiques aux protéines CRISPR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs spécifiques incluent les séquences génétiques uniques des gènes cas."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des protéines CRISPR ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activité peut être évaluée par des tests de coupure d'ADN et d'édition génétique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des dysfonctionnements CRISPR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure des anomalies génétiques et des maladies héréditaires."
}
},
{
"@type": "Question",
"name": "Les protéines CRISPR causent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent survenir, comme des réponses immunitaires indésirables."
}
},
{
"@type": "Question",
"name": "Comment les protéines CRISPR affectent-elles la santé ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent influencer la santé en modifiant des gènes liés à des maladies."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes d'allergie aux protéines CRISPR ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques peuvent survenir, mais elles sont rares et peu documentées."
}
},
{
"@type": "Question",
"name": "Les protéines CRISPR peuvent-elles provoquer des cancers ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications génétiques inappropriées peuvent augmenter le risque de cancer."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées aux protéines CRISPR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des dépistages génétiques et des conseils en génétique."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils intégrer CRISPR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent l'utilisation de CRISPR pour améliorer les vaccins existants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les traitements CRISPR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures incluent le suivi des effets secondaires et l'évaluation des risques."
}
},
{
"@type": "Question",
"name": "Comment éduquer sur les risques des CRISPR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation passe par des campagnes d'information et des ressources en santé publique."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques permettent d'identifier les risques et de prendre des mesures."
}
},
{
"@type": "Question",
"name": "Comment les protéines CRISPR sont-elles utilisées en thérapie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour corriger des mutations génétiques dans des thérapies géniques."
}
},
{
"@type": "Question",
"name": "Quels types de maladies peuvent être traités avec CRISPR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "CRISPR peut traiter des maladies génétiques, des cancers et des infections virales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements en cours avec CRISPR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques explorent l'utilisation de CRISPR pour diverses maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les défis des traitements CRISPR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les défis incluent la précision de l'édition et les effets hors cible potentiels."
}
},
{
"@type": "Question",
"name": "CRISPR peut-il être utilisé pour des maladies infectieuses ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CRISPR est exploré pour cibler et éliminer des virus dans des infections."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CRISPR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des modifications hors cible et des réactions immunitaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des traitements CRISPR ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical rigoureux et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec CRISPR ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences des effets hors cible ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets hors cible peuvent entraîner des mutations indésirables et des maladies."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles, mais cela dépend du cas spécifique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les traitements CRISPR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'état de santé et les antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques augmentent-elles les risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations peuvent accroître le risque de complications avec CRISPR."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il les risques liés à CRISPR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'environnement peut jouer un rôle dans l'expression des gènes modifiés."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs affectent-ils les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements antérieurs peuvent influencer la réponse aux thérapies CRISPR."
}
}
]
}
]
}
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Publications dans "Protéines associées aux CRISPR" :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Electronic address: fengyue@mail.buct.edu.cn.
Publications dans "Protéines associées aux CRISPR" :
Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94143, USA.
Publications dans "Protéines associées aux CRISPR" :
Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: alan.davidson@utoronto.ca.
Publications dans "Protéines associées aux CRISPR" :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Jiangxi Provincial Key Laboratory of Natural Active Pharmaceutical Constituents, Department of Chemistry and Bioengineering, Yichun University, Yichun, China.
Publications dans "Protéines associées aux CRISPR" :
Institute of Pharmacy and Molecular Biotechnology (IPMB), Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany. dominik.niopek@uni-heidelberg.de.
Publications dans "Protéines associées aux CRISPR" :
College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea; Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, 06974, Republic of Korea. Electronic address: xrayleox@cau.ac.kr.
Publications dans "Protéines associées aux CRISPR" :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Jiangxi Provincial Key Laboratory of Natural Active Pharmaceutical Constituents, Department of Chemistry and Bioengineering, Yichun University, Yichun, China.
Publications dans "Protéines associées aux CRISPR" :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China; Key Laboratory of Livestock Infectious Diseases in Northeast China, Ministry of Education, College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, Liaoning Province, Shenyang 110866, China. Electronic address: zeliangchen@yahoo.com.
Publications dans "Protéines associées aux CRISPR" :
RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA; email: Jooyoung.Lee@umassmed.edu, Erik.Sontheimer@umassmed.edu.
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Publications dans "Protéines associées aux CRISPR" :
Robotic surgery has a history of applications in multiple surgical areas and has been applied in plastic surgery over the past decade. Robotic surgery allows for minimal access incisions and decreased...
Mammography shifted to digital breast tomosynthesis (DBT) in the US. An automated percentage of breast density (PD) technique designed for two-dimensional (2D) applications was evaluated with DBT usin...
Background Digital breast tomosynthesis (DBT) plus synthesized mammography (SM) reduces the diagnostic pitfalls of tissue superimposition, which is a limitation of digital mammography (DM). Purpose To...
On the basis of low risk of local recurrence in elderly patients with breast cancer after conservative surgery followed by whole breast irradiation (WBI), the Danish Breast Cancer Group initiated the ...
Patients operated with breast conservation for relatively low-risk breast cancer were randomly assigned to WBI versus PBI, and all had 40 Gy/15 fractions. The primary end point was 3-year grade 2-3 br...
In total, 865 evaluable patients (434 WBI and 431 PBI) were enrolled between 2009 and 2016. Median follow-up was 5.0 years (morbidity) and 7.6 years (locoregional recurrence). The 3-year rate of indur...
External-beam PBI for patients with low-risk breast cancer was noninferior to WBI in terms of breast induration. Large breast size was a risk factor for radiation-associated induration. Few recurrence...
We present a rare case of male axillary accessory breast cancer, which is extremely rare and is indistinguishable from lymphadenopathy and other malignancies, such as lymphoma and skin-derived tumors....
Background Digital breast tomosynthesis (DBT) followed by targeted US is commonly performed to evaluate women with localized breast complaints. However, the added value of DBT in addition to targeted ...
To evaluate the prognostic value of background parenchymal enhancement (BPE) in breast magnetic resonance imaging (MRI) in women referred to radiological department as a high risk for breast cancer....
A retrospective, cross-sectional study included 327 consecutive patients (mean age: 60 years, age range: 30-90 years) who underwent breast MRI and tissue biopsy between 2007 and 2016. All MRI images (...
BPE of bilateral breast showed a weak correlation with FGT (right BPE: r=-0.14, p=0.004; left BPE: r=0.16, p=0.003), a weak negative correlation with patient age (right BPE: r=-0.14, p=0.007; left BPE...
The results of the present study showed no significant correlations between BPE and breast cancer. In addition, there was no significant difference between the right and left breast. Hence, BPE of MRI...
Patients with Stage IV breast cancer are living longer but breast reconstruction in this setting remains controversial. There is limited research evaluating the benefits of breast reconstruction in th...
Drawing from the Mastectomy Reconstruction Outcomes Consortium (MROC) dataset, a prospective cohort study that involved 11 leading medical centers in the US and Canada, we compared patient-reported ou...
Among the MROC population, 26 patients with Stage IV and 2613 women with Stage I-III breast cancer underwent breast reconstruction. Preoperatively, the Stage IV cohort reported significantly lower bas...
The findings in this study suggest that breast reconstruction offers significant quality-of-life benefits for women with advanced breast cancer with no increase in postoperative complications and thus...
The relation between breast induration grade 2-3 at 3 years after radiation therapy and irradiated breast volume was investigated for patients in the Danish Breast Cancer Group (DBCG) Partial Breast I...
Digital Breast Tomosynthesis (DBT) has revolutionized more traditional breast imaging through its three-dimensional (3D) visualization capability that significantly enhances lesion discernibility, red...